The following table shows the calculation of net loss per share (in thousands, except share and per share data):
Weighted average common shares outstanding for the three months ended March 31, 2020 include 1,458,000 shares of common stock issuable on the conversion of pre-funded warrants described in Note 1.
The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti‑dilutive effect:
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Corvus Pharmaceuticals, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020